title: Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal.
authors.affiliation: Haematology Department, San Maurizio Regional Hospital , Bolzano, South Tyrol , Italy .
authors.forename: Andrea
authors.initials: A
authors.lastname: Piccin
authors.forename: Daisy
authors.initials: D
authors.lastname: Corvetta
authors.forename: Ugo
authors.initials: U
authors.lastname: Rovigatti
authors.forename: Guido
authors.initials: G
authors.lastname: Mazzoleni
authors.forename: Irene
authors.initials: I
authors.lastname: Pusceddu
authors.forename: Mirija
authors.initials: M
authors.lastname: Svaldi
authors.forename: Michael
authors.initials: M
authors.lastname: Steurer
authors.forename: Günther
authors.initials: G
authors.lastname: Gastl
authors.forename: Sergio
authors.initials: S
authors.lastname: Cortelazzo
mesh_terms: D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D055016:Megakaryocyte Progenitor Cells / Q000473:pathology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000150:complications*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide
keywords: Anagrelide megakaryoblastic leukaemia; Essential thrombocythemia; chronic myeloid leukemia